How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

640 results for

aspirin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. [Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease]

[Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease] [Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease] [Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease] Park BJ, Park YS, Choi NK, Lee YJ, Kim MS, Lee CW, Kang DY, Park SY, Park JE, Lee NR, Shin JY, Sung JM, Kim SM, Yang BR, Kim HM, Ahn HJ, Kim JY, Go YJ Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Park BJ, Park YS, Choi NK, Lee YJ, Kim MS, Lee CW, Kang DY, Park SY, Park JE, Lee NR, Shin JY, Sung JM, Kim SM, Yang BR, Kim HM, Ahn HJ, Kim JY, Go YJ. [Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A-11-002. 2012 Authors

2012 Health Technology Assessment (HTA) Database.

42. Aspirin resistance in coronary heart disease: Current understandings and strategies Full Text available with Trip Pro

Aspirin resistance in coronary heart disease: Current understandings and strategies 28191510 2019 01 28 2450-131X 4 1 2016 Apr 01 Journal of translational internal medicine J Transl Int Med Aspirin resistance in coronary heart disease: Current understandings and strategies. 7-10 10.1515/jtim-2016-0002 Han Ya-Ling YL Department of Cardiology, General Hospital of Shenyang Military Command, Shenyang 110016, Liaoning Province, China. eng Journal Article 2016 04 14 Poland J Transl Int Med 101673826

2016 Journal of translational internal medicine

43. Does aspirin reduce recurrence after completing anticoagulant treatment for an idiopathic thromboembolic event? Full Text available with Trip Pro

Does aspirin reduce recurrence after completing anticoagulant treatment for an idiopathic thromboembolic event? Idiopathic thromboembolic disease presents a high risk of recurrence. There is controversy about the effects of aspirin in reducing this risk after the completion of anticoagulant treatment. Searching in Epistemonikos database, which screens 30 databases, we identified four systematic reviews that together include two randomized trials. We combined the evidence using meta-analysis (...) and generated a summary of findings table following the GRADE approach. We concluded that aspirin administered after having completed anticoagulation reduces the risk of recurrence, probably without importantly increasing the risk of hemorrhage.

2016 Medwave

44. Understanding why aspirin prevents cancer and why consuming very hot beverages and foods increases esophageal cancer risk. Controlling the division rates of stem cells is an important strategy to prevent cancer Full Text available with Trip Pro

Understanding why aspirin prevents cancer and why consuming very hot beverages and foods increases esophageal cancer risk. Controlling the division rates of stem cells is an important strategy to prevent cancer Cancer is, in essence, a stem cell disease. The main biological cause of cancer is that stem cells acquire DNA alterations during cell division. The more stem cell divisions a tissue accumulates over a lifetime, the higher is the risk of cancer in that tissue. This explains why cancer (...) is diagnosed millions of times more often in some tissues than in others, and why cancer incidence increases so dramatically with age. It may also explain why taking a daily low-dose aspirin for several years reduces the risk of developing and dying from cancer. Since aspirin use reduces PGE2 levels and PGE2 fuels stem cell proliferation, aspirin may prevent cancer by restricting the division rates of stem cells. The stem cell division model of cancer may also explain why regular consumption of very hot

2015 Oncoscience

45. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Full Text available with Trip Pro

Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Aspirin is widely used for secondary prevention after stroke. Cilostazol has shown promise as an alternative to aspirin in Asian people with stroke.To determine the relative effectiveness and safety of cilostazol compared directly with aspirin in the prevention of stroke and other serious vascular events in patients at high vascular risk for subsequent stroke, those with previous transient (...) and contacted trialists and Otsuka Pharmaceutical Co Ltd.We selected all randomised controlled trials (RCTs) comparing cilostazol with aspirin where participants were treated for at least one month and followed systematically for development of vascular events.Data extracted from eligible studies included: (1) a composite outcome of vascular events (stroke, myocardial infarction or vascular death) during follow up (primary outcome); (2) separate outcomes of stroke (ischaemic or haemorrhagic, fatal or non

2011 Cochrane

46. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials

Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

47. Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: a meta-analysis

Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

48. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis

Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

49. Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation

Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

50. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Full Text available with Trip Pro

Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Saini SD, Fendrick AM, Scheiman JM Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of proton-pump inhibitor (PPI) co-therapy to reduce dyspepsia in patients aged 50 years or older, receiving long-term, low-dose aspirin, for the secondary prevention of cardiovascular disease

2011 NHS Economic Evaluation Database.

51. [Dipyridamole and aspirin for secondary prevention after stroke or TIA]

[Dipyridamole and aspirin for secondary prevention after stroke or TIA] Dipyridamol + ASS zur sekundarpravention nach schlaganfall oder TIA [Dipyridamole and aspirin for secondary prevention after stroke or TIA] Dipyridamol + ASS zur sekundarpravention nach schlaganfall oder TIA [Dipyridamole and aspirin for secondary prevention after stroke or TIA] IQWiG Citation IQWiG. Dipyridamol + ASS zur sekundarpravention nach schlaganfall oder TIA. [Dipyridamole and aspirin for secondary prevention after (...) , the data provide an indication (in short-term therapy) and proof (in long-term therapy) that study discontinuations due to AEs are more common with combination therapy. Project page URL Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Aspirin; Dipyridamoles; Ischemic Attack, Transient; Secondary Prevention; Stroke Language Published English Country of organisation Germany English summary An English language summary is available. English Summary English summary available

2011 Health Technology Assessment (HTA) Database.

52. Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin

Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Xie X, McGregor M Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Xie X (...) , McGregor M. Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin. Montreal: Technology Assessment Unit of the McGill University Health Centre (MUHC). Report no. 53. 2011 Authors' conclusions • The applicant intends to use the VerifyNow test to detect those patients at increased risk of arterial thrombotic events due to Clopidogrel resistance. Patients found to be clopidogrel resistant will be treated with other thienopyridine drugs. • The VerifyNow test is easy

2011 Health Technology Assessment (HTA) Database.

53. WITHDRAWN: Antihistamines versus aspirin for itching in late pregnancy. (Abstract)

WITHDRAWN: Antihistamines versus aspirin for itching in late pregnancy. While not common, itching in pregnancy (not due to liver disease) can be distressing.The objective of this review was to assess the effects of treatment for itching in late pregnancy.We searched the Cochrane Pregnancy and Childbirth Group trials register (January 2007).Randomised trials of treatments for itching in women in late pregnancy with normal liver function.Two review authors independently assessed trial quality (...) and extracted data.One study of 38 women was included. This was a small crossover trial, using alternate allocation. The trial compared a histamine, chlorpheniramine, with aspirin. Aspirin was more effective than chlorpheniramine in relieving itching (odds ratio 2.39, 95% confidence interval 1.25 to 4.57). However, chlorpheniramine was more effective than aspirin when a rash was present.Aspirin appears to be more effective than chlorpheniramine for relief of itching in pregnancy when no rash is present

2010 Cochrane

54. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

55. Aspirin following non-arteritic ischaemic optic neuropathy: a systematic review and meta-analysis

Aspirin following non-arteritic ischaemic optic neuropathy: a systematic review and meta-analysis Aspirin following non-arteritic ischaemic optic neuropathy: a systematic review and meta-analysis Aspirin following non-arteritic ischaemic optic neuropathy: a systematic review and meta-analysis Stiebel-Kalish H, Hasanreisoglu M, Leibovici L CRD summary The review concluded that there was a benefit of aspirin in prevention of second eye NAION. However, the evidence was weak (acknowledged (...) by the authors) and concerns about the quality, quantity and heterogeneity of the evidence used to produce the pooled estimate made its reliability questionable. The authors' conclusion should be treated with caution. Authors' objectives To determine the efficacy and safety of aspirin in the prevention of second eye non-arteritic anterior ischaemic optic neuropathy (NAION). Searching MEDLINE and The Cochrane Library were searched without language restrictions up to December 2006. References of all identified

2010 DARE.

56. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis

Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

57. Aspirin use and the risk of gastric cancer: a meta-analysis

Aspirin use and the risk of gastric cancer: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

58. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis

Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

59. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis

Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

60. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Full Text available with Trip Pro

Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Since hypercoagulability might result in recurrent miscarriage, anticoagulant agents could potentially increase the live-birth rate in subsequent pregnancies in women with either inherited thrombophilia or unexplained recurrent miscarriage.To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two miscarriages without (...) in women with a history of at least two miscarriages (up to 20 weeks of amenorrhoea) without apparent causes other than inherited thrombophilia were eligible. Interventions included aspirin, unfractionated heparin, and low molecular weight heparin for the prevention of miscarriage. One treatment could be compared with another or with placebo.Two authors assessed the trials for inclusion in the review and extracted the data. We double checked the data.Two studies (189 participants) were included

2009 Cochrane

Systematic Reviews (Non-Premium)

Systematic reviews are arguably the most important way of telling if an intervention is worthwhile.  As a FREE user you have access to 100,000 less systematic reviews than a Pro user.  Upgrade today.